Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Inclusion Criteria

• •Patients participated in the preceding placebo-controlled Phase 2 study （HB0034-04）and completed at least the Week 12 visit of the HB0034-04 study
• •Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment
• •Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;
• •Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules